Dedicated kidney outcomes trials, like FLOW, are needed to confirm the renoprotective effects of GLP-1RAs
Wongsaroj L, Saninjuk K, Romsang A, Duang-Nkern J, Trinachartvanit W, Vattanaviboon P, et al
The future is digital, and through e-commerce we can create digital options and access that improves patient access, as well as further streamline the prescription workload across the U.S
Conclusions and Relevance The antidepressant properties and tolerability profile of KET01 in these RCTs, including minimal dissociation and cardiovascular effects, support further development of oral KET01 formulation for at-home administration
Additionally, it downregulates fibrosis markers (galectin-3 and -SMA), thus significantly attenuating fibrotic progression (Ahmedy et al., 2022)
They are not for human consumption or use by athletes